Eckol

Cat. No.: HY-114203 CAS No.: 88798-74-7 Molecular Formula: C₁₈H₁₂O₉

372.28 Molecular Weight:

Target: Monoamine Oxidase; Influenza Virus Pathway: Neuronal Signaling; Anti-infection

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

Product Data Sheet

BIOLOGICAL ACTIVITY

Description Eckol is a potent hMAO-A (Mixed) and hMAO-B (non-competitive) inhibitor with IC₅₀s of 7.20 and 83.44 μM, respectively.

Eckol shows stimulatory effects in maize and can be used as a plant biostimulant. Eckol also shows antiallergic and antiviral

effects^{[1][2][3][4]}.

IC₅₀ & Target hMAO-A hMAO-B H1N1

> 7.20 µM (IC₅₀) 83.44 μM (IC₅₀) 89.5 μM (IC₅₀)

In Vitro

Pretreatment with Eckol (25-100 μg/mL; 2 h) significantly reduces β-hexosaminidase release in IgE/BSA-stimulated BMCMC in a dose-dependent manner^[3].

Eckol (25-100 μg/mL; 1 h) inhibits the production of Th2-type cytokines, such as IL-4, IL-5, and IL-13 as well as proinflammatory cytokines, such as IL-6^[3].

Eckol (25-100 μg/mL) attenuates cytokine mRNA levels such as IL-1β, IL-4, IL-5, IL-6, IL-13, IFN-γ, and TNF-α in IgE/BSAstimulated BMCMC^[3].

Eckol (25-100 μg/mL; 1 h) inhibits NF-κB activation in IgE/BSA-stimulated BMCMC^[3].

Eckol showes a moderate IC₅₀ value (89.5 μM) against the influenza A/Bervig-Mission/1/18 (H1N1) virus^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	Bone marrow-derived cultured mast cells (BMCMC)	
Concentration:	25, 50 and 100 μg/mL	
Incubation Time:	1 h	
Result:	Inhibited the degradation of IkB- α within the cytosol and the translocation of the NF-k B/p65 subunit into the nucleus that were induced by IgE/BSA.	

In Vivo

Foliar application of Eckol (1 μM) significantly enhanced shoot and root length, shoot and root fresh and dry weight, leaf area and leaf number^[2].

Eckol (50 or 100 µg/mouse; intradermal; once) reduces allergic inflammatory responses in the passive cutaneous anaphylaxis (PCA)-induced mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice (8 weeks old), IgE/BSA-induced passive cutaneous anaphylaxis (PCA) mode [3]
Dosage:	50 or 100 μg/mouse
Administration:	Intradermal injection, applied on mice ear 2 h prior to anaphylaxis induction
Result:	Reduced allergic inflammatory responses.

REFERENCES

- [1]. Jung HA, et al. Evaluation of the inhibitory effects of eckol and dieckol isolated from edible brown alga Eisenia bicyclis on human monoamine oxidases A and B. Arch Pharm Res. 2017 Apr;40(4):480-491.
- [2]. Rengasamy KR, et al. Enhancing growth, phytochemical constituents and aphid resistance capacity in cabbage with foliar application of eckol--a biologically active phenolic molecule from brown seaweed. N Biotechnol. 2016 Mar 25;33(2):273-9.
- [3]. Han EJ, et al. Eckol from Ecklonia cava Suppresses Immunoglobulin E-mediated Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mice. Nutrients. 2020 May 9;12(5):1361.
- [4]. Besednova NN, et al. Antiviral Effects of Polyphenols from Marine Algae. Biomedicines. 2021 Feb 17;9(2):200.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA